Skip to main content

Table 2 Coexpression of HER-2/neu and p53 in relation to clinicopathological parameters of breast carcinoma

From: Exposure to depleted uranium does not alter the co-expression of HER-2/neu and p53 in breast cancer patients

Parameters Both HER-2/neu and
p53 positive
Only HER-2/neu
positive
Only p53
positive
both HER-2/neu and
p53 negative
Total
Histological type      
Ductal Carcinoma 12
(19.35%)
20
(32.25%)
11
(17.45%)
19
(30.65%)
62
(88.57%)
Lobular Carcinoma 1
(12.50%)
0
(0%)
1
(12.50%)
6
(75%)
8
(11.43%)
  R > 0.3     
Tumor grade      
Well-moderately differentiated
(I and II)
1
(7.14%)
6
(42.86%)
1
(7.14%)
6
(42.86%)
2
(2.86%)
Poorly differentiated (III) 12
(21.43%)
14
(25%)
11
(19.64%)
19
(33.93%)
56
(80%)
  R < 0.3     
Tumor size      
Tis 2
(50%)
2
(50%)
0
(0%)
0
(0%)
4
(5.71%)
T1 0
(0%)
2
(28.57%)
2
(28.57%)
3
(42.86%)
7
(10%)
T2 2
(5.26%)
11
(28.94%)
4
(10.53%)
21
(55.27%)
38
(54.29%)
T3 8
(42.12%)
5
(26.31%)
6
(31.57%)
0
(0%)
19
(27.14%)
T4 1
(50%)
0
(0%)
0
(0%)
1
(50%)
2
(2.86%)
  R > 0.3     
Axillary lymph nodes      
Node +ve
breast cancer
10
(34.49%)
9
(31.03%)
7
(24.14%)
3
(10.34%)
29
(51.79%)
Node-ve
breast cancer
2
(7.41%)
4
(14.81%)
5
(18.52%)
16
(59.26%)
27
(48.21%)
  R < 0.3     
Age of the patient      
< 35 years 8
(4211%)
4
(21.05%)
0
(0%)
7
(36.84%)
19
(27.14%)
> 35years 5
(9.81%)
16
(31.37%)
12
(23.53%)
18
(35.29%)
51
(72.86%)
  R > -0.3     
Tumor recurrence      
Primary 4
(7.84%)
13
(25.49%)
9
(17.65%)
25
(49.02%)
51
(72.86%)
Recurrent 9
(47.37%)
7
(36.84%)
3
(15.79%)
0
(0%)
19
(27.14%)
Total 13
(18.57%)
20
(28.57%)
12
(17.14%)
25
(35.71%)
70
(100%)
  R > 0.3